Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Moderna Inc.’s stock fell 2.6% Friday, after the company said the Food and Drug Administration will not complete its review of the company’s respiratory syncytial virus, or RSV, vaccine by the ...